Refers to Derivatives of pyrimidine compounds of formula (1a) and (1b) where a is a radical optionally substituted with one or several R2, between the same or different, Selected 10 heterocicloalquilo cycloalkyl C3, C3 - 8, aryl and heteroaryl C5 C6 - 15 - 12 Q is a radical, optionally replacing Gone with one or several R4, identical or different,Selected between phenyl heteroaryl C5 - 6 r1 is alkyl C1 - 3, - CF3, - No, among others R2, R4 and R5 are independently H or a radical selected from Ra, RB, among others R3 is - I (or RC), you (or nrcrc, (SC) RC and ra), among others is independently C1 - C6 alkyl aryl - 6, 10, among others R B is a radical selected from =, or - ORCAmong others, RC is a radical selected from H or alkyl aryl C1 - C6 - 6, 10 m, N, P, and q is an integer between 0 and 3.Preferred compounds are: 4 - [4 - ((1R, 2R) - 1 - - - - iloxi metansulfonilamino indan 2 - trifluoromethyl - pyrimidin-2-yl) - 5 - 2 - 3 - methoxy - ilamino] - N - (1 - methyl - 4 - piperidin yl) - benzamide n - ((1R, 2R) - 2 - [2 - [4 - (tert - butyl - piperazin-1-yl) - 2 - methoxy - 3 - trifluoromethyl phenylamino] - pyrimidine - iloxi indan} - 4 - 1 - il) - n-methyl - metansulfon Amide among others. It also relates to a Pharmaceutical composition.These compounds are inhibitors of the Enzyme kinase ptk2, being useful for the treatment of diseases characterized by excessive or abnormal Cell ProliferationSE REFIERE A COMPUESTOS DERIVADOS DE PIRIMIDINAS DE FORMULA (1a) Y (1b) DONDE: A ES UN RADICAL, OPCIONALMENTE SUSTITUIDO CON UNO O VARIOS R2, IGUALES O DIFERENTES, SELECCIONADO ENTRE CICLOALQUILO C3-10, HETEROCICLOALQUILO C3-8, ARILO C6-15 Y HETEROARILO C5-12 Q ES UN RADICAL, OPCIONALMENTE SUSTITUIDO CON UNO O VARIOS R4, IGUALES O DIFERENTES, SELECCIONADO ENTRE FENILO Y HETEROARILO C5-6 R1 ES ALQUILO C1-3, -CF3, -NO , ENTRE OTROS R2, R4 Y R5 SON INDEPENDIENTEMENTE H O UN RADICAL SELECCIONADO ENTRE Ra, Rb, ENTRE OTROS R3 ES -OS(O)Rc, -OS(O)NRcRc, -SC(O)Rc, ENTRE OTROS Ra ES INDE
